|
| 37074838 | Recommendations for economic evaluations of cell and gene therapies: a systematic literature review with critical appraisal. | Expert Rev Pharmacoecon Outcomes Res | 2023 |
| 37579427 | What, Where, and How to Collect Real-World Data and Generate Real-World Evidence to Support Drug Reimbursement Decision-Making in Asia: A reflection Into the Past and A Way Forward. | Int J Health Policy Manag | 2023 |
| 37644739 | Improving Food and Drug Administration-Centers for Medicare and Medicaid Services Coordination for Drugs Granted Accelerated Approval. | Milbank Q | 2023 |
| 37602545 | Turning CMS into a Health Technology Assessment Organization. | N Engl J Med | 2023 |
| 37325997 | Uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group. | Int J Technol Assess Health Care | 2023 |
| 35779824 | Review finds core outcome set uptake in new studies and systematic reviews needs improvement. | J Clin Epidemiol | 2022 |
| 34763929 | Variation in market access decisions for cell and gene therapies across the United States, Canada, and Europe. | Health Policy | 2021 |
| 33577156 | Proposed framework for patient-centered outcomes-based measures in alternative payment models. | Am J Manag Care | 2021 |
| 32438026 | Controversy and Debate Series on Core Outcome Sets. Paper 3: Debate on Paper 1 from the perspective of GRADE [Grading of Recommendations Assessment, Development and Evaluation]. | J Clin Epidemiol | 2020 |
| 31775950 | Implementing health technology assessment in Ghana to support universal health coverage: building relationships that focus on people, policy, and process. | Int J Technol Assess Health Care | 2020 |
| 33041164 | Erratum to "Controversy and debate series on core outcome sets. Paper 3:debate on paper 1 from the perspective of GRADE [Grading of Recommendations Assessment, Development and Evaluation]" [Journal of Clinical Epidemiology 125C (2020) 216-221]. | J Clin Epidemiol | 2020 |
| 32928330 | Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward. | Int J Technol Assess Health Care | 2020 |
| 30744706 | Core Outcome Set-STAndardised Protocol Items: the COS-STAP Statement. | Trials | 2019 |
| 31330522 | The Value of Diagnostic Information in Personalised Healthcare: A Comprehensive Concept to Facilitate Bringing This Technology into Healthcare Systems. | Public Health Genomics | 2019 |
| 31371663 | Introduction. | J Rheumatol | 2019 |
| 31198183 | Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy. | Value Health | 2019 |
| 31129260 | The increasing complexity of the core outcomes landscape. | J Clin Epidemiol | 2019 |
| 29438429 | Choosing important health outcomes for comparative effectiveness research: An updated systematic review and involvement of low and middle income countries. | PLoS One | 2018 |
| 30086771 | Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 Diabetes (SCORE-IT): study protocol for the development of a core outcome set. | Trials | 2018 |
| 29674586 | Insurance coverage for genomic tests. | Science | 2018 |
| 29781145 | Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project. | Haemophilia | 2018 |
| 28077228 | Levers for addressing medical underuse and overuse: achieving high-value health care. | Lancet | 2017 |
| 31245580 | Stakeholder perspectives regarding alternate approaches to informed consent for comparative effectiveness research. | Learn Health Syst | 2017 |
| 28406488 | Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research. | Genet Med | 2017 |
| 28188898 | Rating of Included Trials on the Efficacy-Effectiveness Spectrum: development of a new tool for systematic reviews. | J Clin Epidemiol | 2017 |
| 28159003 | The COMET Initiative database: progress and activities update (2015). | Trials | 2017 |
| 29145404 | Core Outcome Set-STAndards for Development: The COS-STAD recommendations. | PLoS Med | 2017 |
| 29140494 | Comparative Effectiveness Research in Integrative Oncology. | J Natl Cancer Inst Monogr | 2017 |
| 28765256 | Engaging Stakeholders and Promoting Uptake of OMERACT Core Outcome Instrument Sets. | J Rheumatol | 2017 |
| 27864388 | Payer Perspectives on Coverage of Biomarker Testing in Cardiovascular Disease. | Clin Chem | 2017 |
| 26930026 | Patient and clinician support for the learning healthcare system: recommendations for enhancing value. | J Comp Eff Res | 2016 |
| 26633547 | Generating and evaluating evidence of the clinical utility of molecular diagnostic tests in oncology. | Genet Med | 2016 |
| 27755541 | Core Outcome Set-STAndards for Reporting: The COS-STAR Statement. | PLoS Med | 2016 |
| 27487792 | Clinical interventions for venous leg ulcers: Proposals to improve the quality of clinical leg ulcer research. | Wound Repair Regen | 2016 |
| 27070913 | Building Learning Health Systems to Accelerate Research and Improve Outcomes of Clinical Care in Low- and Middle-Income Countries. | PLoS Med | 2016 |
| 26930385 | Improving the relevance and consistency of outcomes in comparative effectiveness research. | J Comp Eff Res | 2016 |
| 25742674 | The views of quality improvement professionals and comparative effectiveness researchers on ethics, IRBs, and oversight. | J Empir Res Hum Res Ethics | 2015 |
| 25669457 | From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients. | Clin Pharmacol Ther | 2015 |
| 24472114 | A national strategy to develop pragmatic clinical trials infrastructure. | Clin Transl Sci | 2014 |
| 30235538 | Understanding the Role and Evidence Expectations of Health Technology Assessment and Coverage/Payer Bodies: What Are They Looking for, and How and Why Does This Differ From What Regulators Require? | Ther Innov Regul Sci | 2014 |
| 25372702 | What can comparative effectiveness research contribute to integrative health in international perspective? | J Altern Complement Med | 2014 |
| 25006877 | Accelerated access to innovative medicines for patients in need. | Clin Pharmacol Ther | 2014 |
| 24856592 | Medical and pharmacy coverage decision making at the population level. | J Manag Care Spec Pharm | 2014 |
| 24634466 | Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer. | Clin Cancer Res | 2014 |
| 24345252 | Interview: a 20-year 'search for evidence' leads to the Center for Medical Technology Policy. | J Comp Eff Res | 2014 |
| 22955111 | Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update. | Genet Med | 2013 |
| 24343113 | Lack of evidence for clinical and health policy decisions. | BMJ | 2013 |
| 23903752 | Breaking a vicious cycle. | Sci Transl Med | 2013 |
| 23919422 | Encouraging value-based insurance designs in state health insurance exchanges. | Am J Manag Care | 2013 |
| 23999501 | Recommendations for the design of Phase 3 pharmaceutical trials that are more informative for patients, clinicians, and payers. | Contemp Clin Trials | 2013 |